Africa's mpox response is less than 10% funded, says Africa CDC

[August 29, 2024]  DAKAR (Reuters) - Africa has secured less than 10% of the estimated $245 million it needs to fight a surging mpox outbreak on the continent, a senior official from the Africa Centers for Disease Control and Prevention (Africa CDC) said on Wednesday.

The continent is under pressure to curb an outbreak of the potentially deadly infection that the World Health Organization declared to be a global health emergency in mid-August, after a new strain began proliferating from Democratic Republic of Congo to neighboring countries.

Africa CDC has pulled together a budget to determine the amount of money available for the mpox response and the resources it needs to mobilize.

"We've come to the first estimate of $245 million," Africa CDC Chief of Staff Ngashi Ngongo said at a WHO meeting in the Republic of Congo's capital Brazzaville.

Democratic Republic of Congo's government has committed $10 million to support the fight against the outbreak while the African Union has approved $10.4 million, Ngongo said.

Therefore, about $20 million is currently available for the response, he said, adding that these figures would be updated.

"The current gap where we stand today is about $224 million that we are looking for," he said.

Furaha Elisabeth applies medication on the skin of her child Sagesse Hakizimana who is under treatment against Mpox, an infectious disease caused by the Mpox virus that causes a painful rash, enlarged lymph nodes and fever, at a health centre in Munigi, Nyiragongo territory, near Goma in North Kivu province of the Democratic Republic of Congo August 19, 2024. REUTERS/Arlette Bashizi/File Photo

Jean Kaseya, director general of Africa CDC, said during the meeting that the organization was moving towards securing almost 1 million doses of mpox vaccine.

Those include 215,000 doses from vaccine maker Bavarian Nordic, 100,000 doses from France, almost 100,000 doses from Germany and about 500,000 doses from Spain.

There is no timeline yet on when the vaccines might reach the Democratic Republic of Congo, which is the most affected by the virus.

Mpox, a viral infection that causes pus-filled lesions and flu-like symptoms, is usually mild but can kill.

(Reporting by Anait Miridzhanian; editing by Jonathan Oatis)

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.